The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib, multicenter, open-label study to assess the safety, tolerability, and preliminary efficacy of sintilimab plus IBI310 (anti-CTLA4 mAb) in patients with advanced hepatocellular carcinoma.
 
Jian Zhou
Research Funding - Innovent Biologics
 
Ying-Hong Shi
Research Funding - Innovent Biologics
 
Baorui Liu
Research Funding - Innovent Biologics
 
Wei-Dong Jia
Research Funding - Innovent Biologics
 
Shanzhi Gu
No Relationships to Disclose
 
Yanru Qin
Research Funding - Innovent Biologics
 
Ying Liu
Research Funding - Innovent Biologics
 
Zhengxiang Han
Research Funding - Innovent Biologics